Trial
NCT06575686
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Phase IISUSPENDEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Recurrent Grade 1 Follicular Lymphoma
Intervention
Biospecimen Collection
Why stopped
Pending Interim Analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-21